Scancell enters strategic collaboration with ImmuneRegen BioSciences

June 4, 2010

By hammersmith

[Source: Pipeline Review] – Scancell Holdings Plc, the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc.. Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen’s Homspera® and Scancell’s ImmunoBody® vaccine technologies.

For more information: Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences